Abiopharma

TAKEDA PHARMACEUTICAL CO., LTD. (TKPHF)

Symbol	TKPHF
Name	TAKEDA PHARMACEUTICAL CO., LTD.
Sector	HEALTH CARE
Region	Asia
Industry	-
Address	103-8668 Japan 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku
Telephone	81 3 3278-2306
Fax	—
Email	—
Website	http://www.takeda.com
Incorporation	JP
Incorporated On	1925
Employees	—
Fiscal Year	3/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	—
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0001395064
Description	Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc. Additional info from NASDAQ: Takeda Pharmaceutical is Japans largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The companys five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Additional info from OTC: Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.

2026-02-10 11:01

Takeda Pharmaceutical Co., Ltd. (TKPHF) Files Form 6-K

2025-12-18 11:03

Takeda Pharmaceutical Co., Ltd. (TKPHF) Files Form 6-K

2025-12-09 11:05

📋 Lauren Rusckowski Duprey (Chief Human Resources Officer) plans to sell 30K shares of Takeda Pharmaceutical Company Limited (at $14.22 each, total $421K) Filed: Dec 09, 2025 | ID: 000006

2025-12-05 11:08

📋 Teresa Marie Bitetti (President, Global Oncology Business Unit) plans to sell 87K shares of Takeda Pharmaceutical Company Limited (at $14.28 each, total $1.2M) Filed: Dec 05, 2025 | ID: 000006

2025-12-04 11:02

📋 Giles Richard Platford (President, Plasma-Derived Therapies Business Unit) plans to sell 58K shares of Takeda Pharmaceutical Company Limited (at $14.31 each, total $836K) Filed: Dec 04, 2025 | ID: 000007

2025-11-28 11:08

Takeda Pharmaceutical Co., Ltd. (TKPHF) Files Form 6-K

2025-11-13 12:58

New Form 13F-HR - TAKEDA PHARMACEUTICAL CO LTD Filed: 2025-11-13 AccNo: 0001395064-25-000157 Size: 7 KB

2025-10-30 10:13

(90% Positive) Takeda Pharmaceutical Co., Ltd. (TKPHF) Reports Q4 2025 Financial Results (Form 6-K)

2025-10-30 10:08

(10% Negative) Takeda Pharmaceutical Co., Ltd. (TKPHF) Reports Q4 2025 Financial Results (Form 6-K)

2025-10-30 10:08

(10% Negative) Takeda Pharmaceutical Co., Ltd. (TKPHF) Reports Q4 2025 Financial Results (Form 6-K)

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07136077	A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Resid…	Phase2	Minimal Residual Disease	Recruiting	2025-09-18	2028-04-01	ClinicalTrials.gov

Total clinical trials: 1

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Fruquintinib	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077
Tislelizumab	Other	Phase PHASE2	Minimal Residual Disease	RECRUITING	NCT07136077

Total products: 20